Skip to main content

Viking Therapeutics, Inc.

corporate_fare Company Profile

Viking Therapeutics, Inc.

VKTX·NASDAQ·Life Sciences·CIK 0001607678

The company is a clinical-stage biopharmaceutical company focused on developing new therapies for metabolic and endocrine disorders. Its primary product candidate is VK2735, a dual agonist targeting the GLP-1 and GIP receptors. VK2735 is being developed in both oral and subcutaneous forms to potentially treat metabolic disorders like obesity. In January 2022, the company began a Phase 1 clinical trial for VK2735, which included single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy adults. This trial evaluated the safety, tolerability, and pharmacokinetics of subcutaneously delivered VK2735. The Phase 1 trial was completed in March 2023. Based on these results, in September 2023, the company initiated the VENTURE study, a Phase 2 clinical trial of VK2735 for patients with obesity. This 13-week study enrolled adults who were obese (BMI >= 30 kg/m2) or overweight (BMI >= 27kg/m2) with at least one weight-related co-morbidity. The study's main goal was to measure the percentage change in body weight from baseline to week 13. Patient enrollment for the Phase 2 VENTURE study was completed in October 2023. On February 27, 2024, the company announced that patients receiving weekly doses of VK2735 showed statistically significant reductions in mean body weight after 13 weeks, up to 14.7% from baseline, and up to 13.1% compared to placebo.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for VKTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Viking Therapeutics Q2 Loss Widens to $128M; Cash $502M; Obesity Pipeline Advances
  • Viking's Obesity Trials Fully Enrolled, Oral VK2735 Phase 3 Set for Q4
  • Viking Therapeutics Faces License Termination for Key Drug Candidate VK2809; Reports Wider Q1 Loss
  • Viking Therapeutics Misses Q1 Estimates as Loss Widens on Higher R&D
  • Viking Therapeutics Files Definitive Proxy, Details Executive Compensation & New Governance Policies

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$359.64M
Diluted EPS
-$3.19
Op. Cash Flow
-$278.69M
Operating Income
-$393.34M
Cash & Equivalents
$165.81M
Debt / Equity
0.00×
Shares Outstanding
114.79M sh
Source: 10-K · filed 2026-02-11 · accession 0001193125-26-046876
$25.1 +1.33% today
52-week range · as of 2026-10-28 $23.82 – $43.15
Market cap
$3.16B
Volume
3.7M (0.8× avg)
3-mo avg 4.3M
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VKTX - Filings & News (Page 2)

VKTX
Jul 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.60
Real-time Price: $25.10 info
Change: -$8.50 (-25%) info
Market Cap: $3.159B info
VKTX
Jul 29, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $33.27
Real-time Price: $25.10 info
Change: -$8.17 (-25%) info
Market Cap: $3.159B info
VKTX
Apr 29, 2026, 9:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.94
Real-time Price: $25.10 info
Change: -$6.84 (-21%) info
Market Cap: $3.159B info
VKTX
Apr 29, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.64
Real-time Price: $25.10 info
Change: -$6.54 (-21%) info
Market Cap: $3.159B info
VKTX
Apr 01, 2026, 4:14 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $33.31
Real-time Price: $25.10 info
Change: -$8.21 (-25%) info
Market Cap: $3.159B info
VKTX
Feb 11, 2026, 5:25 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $31.25
Real-time Price: $25.10 info
Change: -$6.15 (-20%) info
Market Cap: $3.159B info
VKTX
Feb 11, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.76
Real-time Price: $25.10 info
Change: -$3.66 (-13%) info
Market Cap: $3.159B info
VKTX
Jan 05, 2026, 4:30 PM EST
Filing Type: 144
Importance Score:
8
Price at Filing: $32.11
Real-time Price: $25.10 info
Change: -$7.01 (-22%) info
Market Cap: $3.159B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets